Press Releases

Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors
Directors Douglas Leech, Joseph Maroon and Rodney Piatt to Retire from Board

HERTFORDSHIRE, England and PITTSBURGH, May 1, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its Board of Directors has nominated Sjoerd S. Vollebregt as a candidate for election to Mylan's Board at the 2017 Annual Meeting of Shareholders to be held on June 22, 2017. The Board also announced that directors Douglas J. Leech, Joseph C. Maroon and Rodney L. Piatt will retire from the Board effective June 22, 2017 and have not been nominated for reelection at the Annual Meeting. If Mylan's shareholders elect all candidates nominated by the Board at the Annual Meeting, including Vollebregt, Mylan's Board will consist of 11 directors, eight of whom will be independent.

Mylan Chairman Robert J. Coury commented: "On behalf of the entire Board of Directors I want to thank Doug, Joe and Rod for their many years of outstanding service to all of our stakeholders and leadership on the Mylan Board, as well as for their significant contributions to the company, its strategic development and strong growth."

Mr. Coury continued, "As Mylan continues its evolution as a leading global healthcare company, we will continue to seek out additional candidates who can further strengthen our Board by bringing fresh perspectives that can add to our Board's already broad diversity and experience. Nominating Sjoerd accomplishes just that. He brings to Mylan a phenomenal breadth of leadership experience across a variety of industries and a new, independent perspective on how to maximize the many potential opportunities we see ahead for our company. He also brings a strong history of prior senior level executive management experience and currently serves on the boards of directors of other Dutch companies."

Vollebregt currently serves as the chairman of the Supervisory Board of Heijmans N.V., a Euronext Amsterdam listed company operating in property development, residential building, non-residential building, roads and civil engineering, and as chairman of the Advisory Board of Airbus Defence and Space Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris listed company, that develops solar arrays, satellite instruments and structures for launchers. Previously, Vollebregt served as chairman of the Executive Board of Stork B.V., an Amsterdam Stock Exchange-listed industrial group, and as chief executive officer of Fokker Technologies Group B.V., an aerospace company and a Stork B.V. subsidiary. Vollebregt also has previously served as a member of the Supervisory Board of TNT Express N.V., an international courier delivery services company, and has held various other senior positions at Exel plc, Ocean plc, Intexo Holding and Royal Van Ommeren.

Vollebregt said, "I am honored to have been nominated for election to the Mylan N.V Board.  I have had the privilege and opportunity to spend a great deal of time in getting to know Mylan, its Board of Directors and management team, and, if elected, I am very confident that I will be able to contribute to this strong, dynamic group of leaders. Mylan has an extraordinarily rich history of growth and success, and has truly differentiated itself in the global pharmaceutical industry in its quest to benefit shareholders and all other stakeholders."

This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements about how Mylan continues to evolve into a leading global healthcare company and about maximizing the many opportunities Mylan sees ahead for itself. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to any changes in, interruptions to, or difficulties with Mylan's or its partners' ability to develop, manufacture, and commercialize products; the effect of any changes in Mylan's or its partners' customer and supplier relationships and customer purchasing patterns; other changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan or its partners; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on Mylan's or its partners' business; any regulatory, legal, or other impediments to Mylan's or its partners' ability to bring products to market; actions and decisions of healthcare and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and regulations, in the United States and abroad; Mylan's and its partners' ability to protect intellectual property and preserve intellectual property rights; risks associated with international operations; other uncertainties and matters beyond the control of management; and the other risks detailed in Mylan's filings with the Securities and Exchange Commission. Mylan undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We market a growing portfolio of approximately 7,500 products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com. 

SOURCE Mylan N.V.

For further information: Nina Devlin (Media), 724.514.1968; Kris King (Investors), 724.514.1813